公开(公告)号：US20160145334A1

公开(公告)日：2016-05-26

申请号：US14989532

申请日：2016-01-06

申请人： AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

发明人： Mario Mezler ,  Achim Moeller ,  Reinhold Mueller ,  Bernhard K. Mueller ,  Tariq Ghayur ,  Eve H. Barlow ,  Martin Schmidt ,  Axel Meyer ,  Nicole Teusch

IPC分类号： C07K16/28 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/466

摘要： The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

摘要翻译： 本发明涉及结合Nogo-66受体的分离的蛋白质，特别是单克隆抗体。 具体地说，这些抗体具有抑制Nogo-66受体的天然配体结合并中和Nogo-66受体的能力。 本发明的这些抗体或其部分可用于检测NgR和抑制NgR活性，例如在患有NgR或Nogo-66活性有害的病症的人中。

公开(公告)号：US20160075773A1

公开(公告)日：2016-03-17

申请号：US14860499

申请日：2015-09-21

申请人： AbbVie Deutschland GmbH & Co. KG

发明人： Bernhard K. Mueller

IPC分类号： C07K16/18

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

摘要： The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.

摘要翻译： 本申请描述了RGM A结合蛋白，特别是单克隆抗体，特别是其CDR移植的人源化形式，其具有结合RGM A并阻止RGM蛋白与RGM A受体和其他RGM A结合蛋白的结合的能力，以及 因此中和RGM A的功能，用于治疗视网膜神经纤维层（RNFL）变性，以及治疗或预防性治疗哺乳动物抗RNFL变性的方法。

公开(公告)号：US20140065155A1

公开(公告)日：2014-03-06

申请号：US14013916

申请日：2013-08-29

申请人： AbbVie Deutschland GmbH & Co. KG

发明人： Mario Mezler ,  Achim Moeller ,  Reinhold Mueller ,  Bernhard K. Mueller ,  Tariq Ghayur ,  Eve H. Barlow ,  Martin Schmidt ,  Axel Meyer ,  Nicole Teusch

IPC分类号： C07K16/28

CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/466

摘要： The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

摘要翻译： 本发明涉及结合Nogo-66受体的分离的蛋白质，特别是单克隆抗体。 具体地说，这些抗体具有抑制Nogo-66受体的天然配体结合并中和Nogo-66受体的能力。 本发明的这些抗体或其部分可用于检测NgR和抑制NgR活性，例如在患有NgR或Nogo-66活性有害的病症的人中。

公开(公告)号：US20170114129A1

公开(公告)日：2017-04-27

申请号：US15341774

申请日：2016-11-02

申请人： AbbVie Deutschland GmbH & Co. KG

发明人： Bernhard K. Mueller

IPC分类号： C07K16/22

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

摘要： The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.

公开(公告)号：US20210277097A1

公开(公告)日：2021-09-09

申请号：US17026710

申请日：2020-09-21

申请人： AbbVie Deutschland GmbH & Co. KG

发明人： Bernhard K. Mueller

IPC分类号： C07K16/22 ,  C07K16/18

摘要： The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.